APA

Baumgart D. C., Targan S. R., Dignass A. U., Mayer L., van Assche G., Hommes D. W., Hanauer S. B., Mahadevan U., Reinisch W., Plevy S. E., Salzberg B. A., Buchman A. L., Mechkov G. M., Krastev Z. A., Lowder J. N., Frankel M. B. & Sandborn W. J. (20100727). Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. : Inflammatory bowel diseases.

Chicago

Baumgart Daniel C, Targan Stephan R, Dignass Axel U, Mayer Lloyd, van Assche Gert, Hommes Daan W, Hanauer Stephen B, Mahadevan Uma, Reinisch Walter, Plevy Scott E, Salzberg Bruce A, Buchman Alan L, Mechkov Grigor M, Krastev Zahariy A, Lowder James N, Frankel Matthew B and Sandborn William J. 20100727. Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. : Inflammatory bowel diseases.

Harvard

Baumgart D. C., Targan S. R., Dignass A. U., Mayer L., van Assche G., Hommes D. W., Hanauer S. B., Mahadevan U., Reinisch W., Plevy S. E., Salzberg B. A., Buchman A. L., Mechkov G. M., Krastev Z. A., Lowder J. N., Frankel M. B. and Sandborn W. J. (20100727). Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. : Inflammatory bowel diseases.

MLA

Baumgart Daniel C, Targan Stephan R, Dignass Axel U, Mayer Lloyd, van Assche Gert, Hommes Daan W, Hanauer Stephen B, Mahadevan Uma, Reinisch Walter, Plevy Scott E, Salzberg Bruce A, Buchman Alan L, Mechkov Grigor M, Krastev Zahariy A, Lowder James N, Frankel Matthew B and Sandborn William J. Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. : Inflammatory bowel diseases. 20100727.